<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35958596</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: A multicenter, randomized, non-inferiority, controlled trial.</ArticleTitle><Pagination><StartPage>905634</StartPage><MedlinePgn>905634</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">905634</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.905634</ELocationID><Abstract><AbstractText Label="KEY POINT">Considering that vaccination with the sIPV and DTaP overlap at the ages of 3 and 4 months in China, to reduce the burden of treatment on parents and increase vaccination coverage rates, we designed a postmarket clinical study of co-administration.</AbstractText><AbstractText Label="BACKGROUND">The Sabin-strain-based inactivated poliovirus vaccine (sIPV) and the diphtheria-tetanus-acellular pertussis vaccine (DTaP) have been licensed in China for many years. To conduct a clinical study on the safety and immunogenicity of the sIPV when administered concomitantly with the DTaP.</AbstractText><AbstractText Label="METHODS">The study population was divided into three groups: group 1 was the sIPV+ DTaP concomitant administration group, group 2 was the sIPV inoculation group, and group 3 was the DTaP inoculation group. Blood samples were collected prevaccination and 30 days postvaccination, and serum antibody levels were detected.</AbstractText><AbstractText Label="RESULTS">This study showed that the seropositive and seroconversion rates of type 1, 2 and 3 poliovirus in group 1 were higher than those in group 2, with no statistically significant difference after vaccination (P&gt;0.05). Groups 1 and 3 also showed similar responses for all vaccine antigens except anti-FHA (97.65 (94.09-99.36) vs. 100 (97.89-100)). The geometric mean titers (GMTs) for the DTaP and sIPV among the groups were comparable, and the non-inferiority t test result was P&lt;0.001. The number of local adverse events (AEs) reported in group 1 (29.91%) were larger than those in group 2 (12.39%) and group 3 (21.93%), among which the most common was redness. Similarly, the most common systemic AE was fever. All 5 severe AE (SAE) cases were determined by experts to be unrelated to the vaccines during the study.</AbstractText><AbstractText Label="CONCLUSIONS">The evidence of similar seroconversion and safety with co-administered DTaP and sIPV supports the co-administration supports the introduction of a strategy of simultaneous administration of both vaccines into routine infant immunization, and it could increase vaccination coverage and protect more infants from morbidity and mortality from these related diseases.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION">https://clinicaltrials.gov/ct2/show/NCT04054882?term=NCT04054882&amp;cntry=CN&amp;draw=2&amp;rank=1, identifier NCT04054882.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Sun, Xu, Tang, Xiao, Wang, Wang, Zhu, Yang and Chen.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Fenyang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yanhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Affairs, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhiguo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Binbing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Anhui Provincial Center for Disease Control and Prevention, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Sichuan Provincial Center for Disease Control and Prevention, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medical Affairs, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Haiping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Affairs, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04054882</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022681">Diphtheria-Tetanus-acellular Pertussis Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000907" MajorTopicYN="N">Antibodies, Bacterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004165" MajorTopicYN="Y">Diphtheria</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022681" MajorTopicYN="Y">Diphtheria-Tetanus-acellular Pertussis Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013742" MajorTopicYN="Y">Tetanus</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014917" MajorTopicYN="Y">Whooping Cough</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DTaP</Keyword><Keyword MajorTopicYN="N">concomitant administration</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">sIPV</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">vaccine interference</Keyword></KeywordList><CoiStatement>YH X, HC and XY are employees of China National Biotec Group Company Limited. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>3</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35958596</ArticleId><ArticleId IdType="pmc">PMC9361845</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.905634</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koslap-Petraco MB, Judelsohn RG. Societal impact of combination vaccines: experiences of physicians, nurses, and parents. J Pediatr Health Care (2008) 22:300&#x2013;9. doi: 10.1016/j.pedhc.2007.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pedhc.2007.09.004</ArticleId><ArticleId IdType="pubmed">18761231</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Rodewald L, Yang J, Qin Y, Pang M, Feng L, et al. . The landscape of vaccines in China: history, classification, supply, and price. BMC Infect Dis (2018) 18:502. doi: 10.1186/s12879-018-3422-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3422-0</ArticleId><ArticleId IdType="pmc">PMC6172750</ArticleId><ArticleId IdType="pubmed">30286735</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobanjo-Ter MA, Duclos P, McIntyre P, Lewis KD, Van Damme P, O'Brien KL, et al. . Assessing the evidence for maternal pertussis immunization: a report from the bill &amp; melinda gates foundation symposium on pertussis infant disease burden in low- and lower-middle-income countries. Clin Infect Dis (2016) 63:S123&#x2013;33. doi: 10.1093/cid/ciw530</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciw530</ArticleId><ArticleId IdType="pmc">PMC5106619</ArticleId><ArticleId IdType="pubmed">27838664</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S, Chen H, Zhang Z, Chang S, Xiao Y, Luo L, et al. . Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China. VACCINE (2020) 38:6274&#x2013;9. doi: 10.1016/j.vaccine.2020.07.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.07.042</ArticleId><ArticleId IdType="pubmed">32747216</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YS. Analysis on the deveiopment trend and problems of combined vaccine industry in China. Chin J Pharm (2018) 49:1306&#x2013;12. SQ WLEA. doi:&#xa0;10.16522/j.cnki.cjph.2018.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.16522/j.cnki.cjph.2018.09.016</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, et al. . Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis (2015) 15:1273&#x2013;82. doi: 10.1016/S1473-3099(15)00219-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00219-4</ArticleId><ArticleId IdType="pubmed">26318714</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, et al. . Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis (2010) 201:1344&#x2013;52. doi: 10.1086/651611</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/651611</ArticleId><ArticleId IdType="pubmed">20350164</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, et al. . Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. LANCET (2015) 386:2413&#x2013;21. doi: 10.1016/S0140-6736(15)00237-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00237-8</ArticleId><ArticleId IdType="pubmed">26388534</ArticleId></ArticleIdList></Reference><Reference><Citation>
China NMPA . Guiding principles for classifification criteria of adverse events in vaccine clinical trials. (2015). Available at: https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20191231111901460.html.</Citation></Reference><Reference><Citation>Liao G, Li R, Li C, Sun M, Jiang S, Li Y, et al. . Phase 3 trial of a sabin strain-based inactivated poliovirus vaccine. J Infect Dis (2016) 214:1728&#x2013;34. doi: 10.1093/infdis/jiw433</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw433</ArticleId><ArticleId IdType="pubmed">27658691</ArticleId></ArticleIdList></Reference><Reference><Citation>Guang Z HL MX. Immunogenicity and immune persistence of adsorbed diphtheria,tetanus and acellular pertussis combined vaccine. Chin J Biol (2013) 26:1805&#x2013;8. doi:&#xa0;10.13200/j.cnki.cjb.000021</Citation><ArticleIdList><ArticleId IdType="doi">10.13200/j.cnki.cjb.000021</ArticleId></ArticleIdList></Reference><Reference><Citation>Behre U, van der Meeren O, Crasta P, Hanssens L, Mesaros N. Lasting immune memory against hepatitis b in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy. Hum Vaccin Immunother (2016) 12:2916&#x2013;20. doi: 10.1080/21645515.2016.1202388</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2016.1202388</ArticleId><ArticleId IdType="pmc">PMC5137516</ArticleId><ArticleId IdType="pubmed">27653771</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher MA, Fabre P, Debois H, Saliou P. Vaccines administered simultaneously: directions for new combination vaccines based on an historical review of the literature. Int J Infect Dis (2004) 8:328&#x2013;38. doi: 10.1016/j.ijid.2004.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2004.03.006</ArticleId><ArticleId IdType="pubmed">15494254</ArticleId></ArticleIdList></Reference><Reference><Citation>Anh DD, van der Meeren O, Karkada N, Assudani D, Yu TW, Han HH. Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: An open-label, phase III study. Hum Vaccin Immunother (2016) 12:655&#x2013;7. doi: 10.1080/21645515.2015.1084451</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1084451</ArticleId><ArticleId IdType="pmc">PMC4964705</ArticleId><ArticleId IdType="pubmed">26337197</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Li RC, Ye Q, Li C, Liu YP, Ma X, et al. . Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants. Hum Vaccin Immunother (2017) 13:588&#x2013;98. doi: 10.1080/21645515.2016.1239670</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2016.1239670</ArticleId><ArticleId IdType="pmc">PMC5360111</ArticleId><ArticleId IdType="pubmed">27768515</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Gao Z, Bai S, Liu X, Han S, Xiao Y, et al. . Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement. Vaccine (2021) 39:2467&#x2013;74. doi: 10.1016/j.vaccine.2021.02.073</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.02.073</ArticleId><ArticleId IdType="pubmed">33810904</ArticleId></ArticleIdList></Reference><Reference><Citation>
CNBG CB . The inactivated polio vaccine produced by China biotechnology co. LTD has been pre-certified by the world health organization. (2022). Available at: https://www.cnbg.com.cn/#/newsDet.ail?cid=25&amp;id=765.</Citation></Reference><Reference><Citation>Li Z, Xu J, Tan H, Zhang C, Chen J, Ni L, et al. . Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in guangzhou, China, from 2011 to 2017. Int J Infect Dis (2020) 99:149&#x2013;55. doi: 10.1016/j.ijid.2020.07.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.07.019</ArticleId><ArticleId IdType="pubmed">32795602</ArticleId></ArticleIdList></Reference><Reference><Citation>Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr Infect Dis J (2008) 27:341&#x2013;6. doi: 10.1097/INF.0b013e3181616180</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181616180</ArticleId><ArticleId IdType="pubmed">18316985</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Hwang HS, Kim JH, Kim HH, Lee HS, Chung EH, et al. . Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the republic of Korea. Vaccine (2011) 29:1551&#x2013;7. doi: 10.1016/j.vaccine.2010.12.094</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.12.094</ArticleId><ArticleId IdType="pubmed">21215828</ArticleId></ArticleIdList></Reference><Reference><Citation>Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis (2003) 14:196&#x2013;8. doi: 10.1016/S1045-1870(03)00033-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1045-1870(03)00033-5</ArticleId><ArticleId IdType="pubmed">12913831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan EJ, Nilsson L, Kjellman N, Gothefors L, Mills KH. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. Clin Exp Immunol (2000) 121:193&#x2013;200. doi: 10.1046/j.1365-2249.2000.01306.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.2000.01306.x</ArticleId><ArticleId IdType="pmc">PMC1905694</ArticleId><ArticleId IdType="pubmed">10931131</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xe4;rng&#xe5;rd O, Nilsson L, F&#xe5;hraeus C, Gustafsson L, Hallander HO, Olin P, et al. . Catch-up primary vaccination with acellular pertussis vaccines in 3-4-year-old children&#x2013;reactogenicity and serological response. Vaccine (1998) 16:480&#x2013;4. doi: 10.1016/S0264-410X(97)00224-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(97)00224-7</ArticleId><ArticleId IdType="pubmed">9491502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Z. Observation on adverse reactions of diphtheria, tetanus and pertussis vaccination in different parts. Chin J Clin Rational Drug Use (2014) 9:22&#x2013;3. doi:&#xa0;10.15887/j.cnki.13-1389/r.2014.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.15887/j.cnki.13-1389/r.2014.09.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie YL LHLH. Causes and countermeasures of adverse reactions to diphtheria-pertussis-tetanus vaccination. Chin J Natural Med (2009) 6:446&#x2013;8. doi:&#xa0;10.16505/j.2095-0136.2009.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.16505/j.2095-0136.2009.06.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim FS, Phua KB, Lee BW, Quak SH, Teoh YL, Ramakrishnan G, et al. . Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting. Southeast Asian J Trop Med Public Health (2011) 42:138&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">21323176</ArticleId></ArticleIdList></Reference><Reference><Citation>Saenger R, Maechler G, Potreck M, Zepp F, Knuf M, Habermehl P, et al. . Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately. VACCINE (2005) 23:1135&#x2013;43. doi: 10.1016/j.vaccine.2004.08.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.08.030</ArticleId><ArticleId IdType="pubmed">15629356</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Li FX, Hou QM, Li CG, Li YN, Chen FS, et al. . [Immunogenicity and safety of DTaP-IPV//PRP-T combined vaccine in infants in China]. Zhonghua Liu Xing Bing Xue Za Zhi (2011) 32:808&#x2013;15. doi:&#xa0;10.3760/cma.j.issn.0254-6450.2011.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0254-6450.2011.08.017</ArticleId><ArticleId IdType="pubmed">22093474</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu K, Ying Z, Wang L, Hu Y, Xia J, Chen L, et al. . Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Vaccine (2018) 36:6782&#x2013;9. doi: 10.1016/j.vaccine.2018.09.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.023</ArticleId><ArticleId IdType="pubmed">30249424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Wang J, Zeng G, Chu K, Jiang D, Zhu F, et al. . Immunogenicity and safety of a Sabin strain-based inactivated polio vaccine: A phase 3 clinical trial. J Infect Dis (2019) 220:1551&#x2013;7. doi: 10.1093/infdis/jiy736</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy736</ArticleId><ArticleId IdType="pubmed">30958543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Xu K, Han W, Chu K, Jiang D, Wang J, et al. . Safety and immunogenicity of Sabin strain inactivated poliovirus vaccine compared with Salk strain inactivated poliovirus vaccine, in different sequential schedules with bivalent oral poliovirus vaccine: Randomized controlled noninferiority clinical trials in China. Open Forum Infect Dis (2019) 6:z380. doi: 10.1093/ofid/ofz380</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofz380</ArticleId><ArticleId IdType="pmc">PMC6786509</ArticleId><ArticleId IdType="pubmed">31660344</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>